Connor Clark & Lunn Investment Management Ltd. Acquires 14,956 Shares of Neurocrine Biosciences, Inc. (NASDAQ:NBIX)

Connor Clark & Lunn Investment Management Ltd. lifted its stake in Neurocrine Biosciences, Inc. (NASDAQ:NBIX) by 670.7% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 17,186 shares of the company’s stock after purchasing an additional 14,956 shares during the period. Connor Clark & Lunn Investment Management Ltd.’s holdings in Neurocrine Biosciences were worth $1,980,000 at the end of the most recent quarter.

Several other institutional investors also recently added to or reduced their stakes in NBIX. Sumitomo Mitsui DS Asset Management Company Ltd grew its stake in Neurocrine Biosciences by 0.8% in the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 11,436 shares of the company’s stock worth $1,574,000 after acquiring an additional 90 shares in the last quarter. Fifth Third Bancorp increased its holdings in Neurocrine Biosciences by 14.7% during the 2nd quarter. Fifth Third Bancorp now owns 716 shares of the company’s stock worth $99,000 after purchasing an additional 92 shares during the period. Total Clarity Wealth Management Inc. raised its position in Neurocrine Biosciences by 4.3% during the 2nd quarter. Total Clarity Wealth Management Inc. now owns 2,433 shares of the company’s stock valued at $335,000 after purchasing an additional 100 shares in the last quarter. Commerce Bank raised its position in Neurocrine Biosciences by 2.6% during the 3rd quarter. Commerce Bank now owns 4,199 shares of the company’s stock valued at $484,000 after purchasing an additional 108 shares in the last quarter. Finally, Caprock Group LLC lifted its holdings in shares of Neurocrine Biosciences by 7.0% in the 2nd quarter. Caprock Group LLC now owns 1,669 shares of the company’s stock worth $230,000 after buying an additional 109 shares during the period. Hedge funds and other institutional investors own 92.59% of the company’s stock.

Neurocrine Biosciences Stock Up 1.2 %

Shares of NBIX stock opened at $127.11 on Tuesday. The stock has a market cap of $12.87 billion, a PE ratio of 34.08 and a beta of 0.35. Neurocrine Biosciences, Inc. has a 52-week low of $110.52 and a 52-week high of $157.98. The business has a 50-day simple moving average of $118.62 and a 200-day simple moving average of $131.89.

Analyst Ratings Changes

Several brokerages have issued reports on NBIX. Barclays dropped their target price on shares of Neurocrine Biosciences from $180.00 to $160.00 and set an “overweight” rating on the stock in a report on Monday, September 9th. Guggenheim increased their target price on Neurocrine Biosciences from $170.00 to $180.00 and gave the company a “buy” rating in a research report on Friday, August 2nd. Cantor Fitzgerald reissued an “overweight” rating and issued a $155.00 price target on shares of Neurocrine Biosciences in a research report on Monday, September 16th. Robert W. Baird raised their price objective on Neurocrine Biosciences from $157.00 to $180.00 and gave the company an “outperform” rating in a research report on Friday, August 2nd. Finally, JPMorgan Chase & Co. increased their price target on shares of Neurocrine Biosciences from $173.00 to $181.00 and gave the company an “overweight” rating in a research report on Wednesday, August 7th. Five research analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, Neurocrine Biosciences currently has a consensus rating of “Moderate Buy” and a consensus target price of $163.91.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company’s products include INGREZZA for tardive dyskinesia and chorea associated with Huntington’s disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.